All In MedTech

FDA Clearance Tracker · P220029-S002

Optilume™ BPH Catheter System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 15, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 15, 2024

Approved

Time to decision

86 days

Received May 21, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P220029-S002
Device name
Optilume™ BPH Catheter System
Applicant location
Minneapolis, MN
Received
May 21, 2024
Decided
Aug 15, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P220029

Device type

Device class
Class III

Every decision under product code QXB

FDA's approval statement

As written in FDA's record.

approval for a change in supplier for two kit components (i.e., the Tuohy-Borst adapter and stopcock), a change in kit packaging of the components (i.e., addition of the Tuohy-Borst adapter and Stopcock to the Pre-Dilation Catheter Tyvek Pouch), and a change in labeling to remove the vascular meta-analysis information from the Instructions for Use

Source documents

Other decisions for Urotronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.